Form 4: Cytokinetics CCO Andrew Callos Reports Equity Changes

Cytokinetics' Chief Commercial Officer, Andrew Callos, reported the acquisition of performance shares and a tax-related disposition, resulting in a net increase in his direct beneficial ownership.

Summary

• Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc. (CYTK), reported transactions on December 22, 2025.
• He acquired 1,589 shares of Common Stock as performance shares that vested immediately.
• He also acquired 1,588 shares of Common Stock as performance shares, which are subject to a 1-year vesting requirement.
• A disposition of 675 shares of Common Stock occurred at a price of $62.72 per share for tax withholding purposes on the vesting of performance shares.
• Following these transactions, Mr. Callos directly beneficially owns 53,162 shares of Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the insider's net acquisition of shares, indicating confidence in the company, despite a portion being disposed for tax purposes which is a routine event.

Positives

• Andrew Callos earned 3,177 performance shares (1,589 immediately vested and 1,588 subject to 1-year vesting) upon achieving performance goals, indicating successful performance metrics.
• The net effect of the transactions is an increase in Mr. Callos's direct beneficial ownership of Cytokinetics Common Stock.

Negatives

• 675 shares were disposed of to cover tax withholding obligations on the vesting of performance shares, reducing the total number of shares held.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The net increase in an executive's direct beneficial ownership could be viewed as a minor positive signal of management's alignment with shareholder interests.

Key Dates

Keywords

Cytokinetics, CYTK, Andrew Callos, Chief Commercial Officer, EVP, SEC Form 4, Insider Trading, Equity, Performance Shares, Stock Acquisition, Tax Withholding